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ABSTRAK 
Psoriasis menyebabkan beban ekonomi yang besar akibat perbelanjaan yang tinggi 
untuk rawatan, prosedur diagnostik, farmaseutikal dan kehilangan produktiviti. 
Maklumat berkenaan beban ekonomi amatlah terhad. Kajian ini bertujuan untuk 
mengira kos berkaitan dengan empat jenis rawatan psoriasis. Kajian prospektif 
kohort telah dijalankan di lima buah hospital melibatkan 91 pesakit psoriasis 
sederhana dan teruk. Kos dikira daripada perspektif masyarakat menggunakan 
prinsip “Step Down” dan “Activity Based Costing” dalam tempoh enam bulan 
rawatan susulan. Komponen kos yang ditanggung oleh pembekal adalah kos 
pesakit dalam, kos ubat ubatan, kos makmal penyiasatan dan radiologi. Kos pesakit 
pula adalah perbelanjaan poket untuk pengangkutan dan kehilangan produktiviti. 
Kos sehari bagi pesakit dalam adalah sebanyak RM1,105.24 (US$315.94) dan 
kos pesakit luar bagi setiap lawatan adalah RM298.02 (US$85.19). Ubat-ubatan 
menyumbang hampir 90% (RM457,014.00) (US$130,638.45) daripada jumlah 
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keseluruhan kos pembekal. Sementara itu, kehilangan produktiviti menyumbang 
84% (RM167,439.00) (US$47,862.80) daripada jumlah keseluruhan kos pesakit. 
Rawatan biologik menunjukkan kos yang paling tinggi iaitu sebanyak RM342,377.00 
(US$97,869.21), diikuti oleh rawatan sistemik (RM105,607.00) (US$30,187.99), 
rawatan topikal (RM38,280.00) (US$10,942.42) dan rawatan fototerapi 
(RM21,824.00) (US$6,238.44). Memahami hubungan antara kos langsung dan 
tidak langsung dari kedua-dua perspektif adalah penting untuk mengenal pasti 
dan menilai rawatan yang paling berkesan untuk psoriasis. 
Kata kunci: analisis kos, psoriasis, Malaysia
  ABSTRACT 
Psoriasis imposes a great economic burden as a result of higher expenditures 
for different interventions, diagnostic procedures, pharmaceuticals and loss of 
productivity. Less is known about the economic impact of psoriasis treatment in 
Asean region. The aim of this research was to calculate the costs associated with 
four psoriasis treatment modalities. A prospective cohort study was conducted 
in five hospitals involving 91 moderate to severe psoriasis patients. Costs were 
calculated from the societal perspective using the principle of Step Down and 
Activity Based Costing (ABC) within a six (6) months follow-up duration. The 
components of the costs borne by the provider were inpatient cost, cost of 
medication, laboratory investigation and radiology. Patient’s cost included out of 
pocket expenses, travelling cost and loss of productivity. Cost per patient per day 
was RM1,105.24 (inpatient) (US$315.94) and RM298.02 (outpatient) (US$85.19). 
Medication accounted for almost 90% (RM457,014.00) (US$130 638.45) of the total 
provider cost. Meanwhile, loss of productivity represented 84% (RM167,439.00) 
(US$47,862.80) of the total patient’s cost. Biologic treatment exhibited the highest 
cost which was RM342,377.00 (US$97,869.21), followed by systemic treatment 
(RM105,607.00) (US$30,187.99), topical treatment (RM38,280.00) (US$10,942.42) 
and topical phototherapy treatment (RM21,824.00) (US$6,238.44). Understanding 
the relationship between direct and indirect costs from both perspectives is 
important to accurately identify and evaluate effective treatment for psoriasis.
Keywords: cost analysis, psoriasis, Malaysia
patients reported that the disease had 
a moderate to great negative impact 
on their quality of life and poses great 
economy burden (Augustin et al. 2008; 
Tang et al. 2013). Treatment available 
for psoriasis patients include topical, 
 INTRODUCTION
Psoriasis is a chronic dermatology 
disease that affects 1-3% of the world’s 
population (Colombo et al. 2008; 
Stern et al. 2004). The majority of the 
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phototherapy, systemic and biologic. 
Treatment is based on the severity of 
the illness (mild, moderate, or severe). 
Topical treatment is given to patients 
with mild severity while phototherapy 
treatment is administered to moderate 
to severe cases of psoriasis (who 
have failed the topical treatments) 
before starting them on systemic and 
biologics (Ministry of Health 2013; 
Morrow 2006; Schmitt & Ford 2006). 
Therapy options have a substantial 
effects on the overall costs related to 
psoriasis (Pearce et al. 2006; Steinke 
et al. 2013). Annual costs associated 
with psoriasis treatment modalities 
was up to RM42 billion (€7 billion) 
in Germany and up to RM58 billion 
(US$11 billion) in the United States 
(Morrow 2006; Schmitt & Ford, 2006). 
As the management for psoriasis evolve 
from inpatient to outpatient care, 
many patients would need lifelong 
care and expensive treatments such 
as systemic and biologic (Pearce et al. 
2006). At a tertiary care level, the cost 
could increase up to 20 times more 
due to the different interventions used 
(Ferrándiz et al. 2010; Raho et al. 2012). 
Comorbidities such as cardiovascular 
disease and depression, that are 
associated with psoriasis patients, may 
escalate the treatment costs (Mustonen 
et al. 2014). 
 Biologics have revolutionised the 
management of psoriasis. However, 
greater cost associated with biologic 
medication might hinder its use in 
clinical settings (Chen et al. 2014; 
Mantovani et al. 2016; Vañó-Galván 
et al. 2012). In the light of shrinking 
health and care budget combined with 
limited health care resources, treatment 
regiments should be evaluated in 
relative to their cost and effectiveness 
(Ellis & Barker 2000). There is not 
much research on the cost of treatment 
for psoriasis in this region. Therefore, 
this study aimed at estimating the 
costs associated with four different 
psoriasis treatment in Malaysian public 
hospitals. 
MATERIALS AND METHODS
This was a prospective cohort study 
to evaluate the cost of four psoriasis 
treatments i.e. topical; topical and 
phototherapy; topical and systemic; 
topical and biologic, at four public 
hospitals, namely Hospital Kuala 
Lumpur (HKL), Hospital Sultanah 
Aminah Johor Bahru (HSAJB), Hospital 
Sultanah Bahiyah (HSB), Hospital 
Pulau Pinang (HPP) and the Universiti 
Kebangsaan Malaysia Medical Centre. 
Respondents were moderate to 
severe psoriasis patients attending the 
Dermatology Clinic at these hospitals 
from November 2015 until March 
2017. The selection of the respondents 
in this study was based on the criteria 
as illustrated in Sulong et al. (2016). 
 A cost analysis was conducted from 
a societal perspective. Components of 
the costs borne by the provider include 
capital cost (building cost), recurrent 
cost (emolument, consumables, utilities 
and maintenance) and direct costs 
(medication, laboratory investigation 
and radiological examination). Costing 
methods in this study was as per 
description by Sulong et al. (2016). 
Various components of the provider’s 
cost were shared with other services 
provided by the hospitals. Hence, the 
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allocation method was used based 
on the ratio of psoriasis patients as 
inpatients (number of days) and ratio of 
psoriasis patients as outpatients to the 
clinic per year (Sharifa Ezat et al. 2009) 
(Table 1). 
RESULTS 
A total of 91 patients were recruited for 
this study. Demography of the majority 
of the patients were as follows: males 
(56[62%]), aged more than 35 years 
old (58[63%]), Malays (61[67%]), higher 
education (33[35%], married (62[68%]) 
and employed (85[93%]) with income 
between RM0-3000.00 (49[54%]). 
Majority of the patients received topical 
and systemic treatment (40[44%]), 
followed by topical (32[35%]), topical 
and biologic (10[11%]) and topical and 
phototherapy (9[10%] (Table 2). 
 Table 3 shows the estimated cost of 
treatment of psoriasis for six months 
duration. Cost of treating psoriasis 
in this cohort was RM706,416.00 
with cost per patient at RM7,762.81. 
Medication exhibited the highest cost 
which was almost 90% of the total 
provider cost (RM457,014.00; cost 
per patient was RM5,022.13) followed 
by laboratory tests (RM49,329.00; 
cost per patient was RM542.08) and 
radiology (RM1,744.00; cost per patient 
was RM19.16). From the patient’s 
perspective, loss of productivity was the 
greatest cost (RM167,448.00; cost per 
patient was RM1,840.09), followed by 
out of pocket payments (RM20,610.00; 
cost per patient was RM226.48) and 
travelling cost (RM10,271.00; cost per 
patient was RM112.87). Table 4 shows 
Approach Component of cost Measure Formula
STEP 
DOWN
Inpatient cost Cost per patient per day
•60% of the annual operational cost (a)
•Ratio inpatient days medical to inpatient days all 
department (b)
•Operational cost medical department (c) = a x b
•Ratio inpatient days psoriasis to inpatient days 
medical (d)
•Operational inpatient cost  psoriasis (e) = c x d
•Average inpatient days of psoriasis (f)
•Average cost of inpatient psoriasis per patient 
per day (g) 
•= e / f
Outpatient 
cost
Cost patient per 
visit
•40% of the annual operational cost (1)
•Ratio outpatient visit medical to outpatient visit 
all department (2)
•Operational cost medical department (3) = 1 x 2
•Ratio outpatient visit psoriasis to outpatient visit 
medical (4)
•Operational outpatient cost psoriasis (5) = 3 x 4
•Average outpatient visit psoriasis (6)
•Average cost of outpatient psoriasis per patient 
per visit (7) 
•= 5 / 6
Table 1: Calculation model
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Characteristics n %
Age 19-25 10 11
26-35 23 25
36-55 32 35
56-80 26 28
Gender Male 56 62
Female 35 38
Ethnicity Malays 61 67
Chinese 20 22
Indians 10 11
Education No schooling 1 1
Secondary + primary 57 64
Diploma 16 18
Degree 15 16
Others 2 1
Marital Status Single + divorced 29 32
Married 62 68
Occupation Unemployed 6 7
Employed 85 93
Income (RM) No income 21 23
<1000 7 8
1001-3000 42 46
3001-5000 17 19
>5000 4 4
Treatment Topical 32 35
Topical and phototherapy 9 10
Topical and systemic 40 44
Topical and biologic 10 11
Table 2: Demographic profile of the respondents 
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inpatient and outpatient costs. It was 
estimated that cost per patient per day 
for inpatients was RM1,105.24 and cost 
per patient per visit for outpatients was 
RM298.02. There was a significant 
difference across the group in all 
modalities for provider’s and patient’s 
costs (p<0.05). From provider's 
perspective, topical and biologic 
exhibited greatest medication cost, with 
RM333,295.00, meanwhile, topical and 
systemic yielded highest lab test and 
radiology test with RM26,565.00 and 
RM850.00 respectively. From patient's 
perspective, topical and phototherapy 
produced highest productivity cost 
with RM73,170.00, while topical and 
systemic produced greatest traveling 
cost with RM3960.00. On the other 
hand, topical incurred highest out of 
pocket payments with RM8,430.00 
(Table 5).
DISCUSSION 
In this study, the cost estimation for 
treating psoriasis in this cohort (6 
months follow-up) was RM706,416.00 
with cost per patient at RM7,762.81. A 
previous study conducted by Tang et 
al. (2013) showed that the estimated 
cost of the treatment of psoriasis was 
RM1,307.47/person/year (year 2007). 
The number of participants, severity 
of the illness, component of costs, and 
the principle of costing might explain 
the difference in costs. All respondents 
in this study had moderate to severe 
psoriasis, which has been proven to 
impose greater economic burden 
than mild psoriasis (Balogh et al. 2014; 
Gospodarevskaya et al. 2009; Sohn 
et al. 2006; Steinke et al. 2013). In 
addition, inflation could be another 
cause for the greater costs estimated 
in this study. This study utilised micro 
costing, ABC which provides the most 
Perspective Cost (RM) Cost per patient 
(n=91)
Annual cost 
(2015)
Provider 
RM1,290, 869.46
•Medication RM 457,014.00 RM  5,022.13
• Lab tests RM  49,329.00 RM    542.08
• Radiology RM    1,744.00 RM       19.16
Overall provider cost RM 508,087.00 RM 5,583.37
Patient 
• Out of pocket payments RM  20,610.00 RM    221.54
• Traveling cost RM  10,271.00 RM    112.87
• Loss of productivity RM 167,448.00 RM 1,840.09
Overall patient cost RM 198,329.00 RM 2,179.44
Societal (patient + provider 
cost)
RM 706,416.00 RM  7,762.81
Table 3: Overall cost for treating psoriasis in Malaysia 
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precise cost estimation than macro 
costing (Drummond et al. 2015).
 The cost of the treatment of psoriasis 
is well studied (Colombo et al. 2008; 
Crown et al. 2004; Mustonen et al. 
2014; Balogh et al. 2014). However, 
the evidence concerning the 
economic impact of the treatment of 
psoriasis is limited in this region. In 
the USA, the cost of treating psoriasis 
was RM28,628.00 (US$6,422.00) 
patient/year (Vanderpuye-Orgle et 
al. 2015). A study conducted by Levy 
et al. (2012) showed that the annual 
cost for treating psoriasis in Canada 
was RM5.9 billion (US$1.7 billion) 
with cost per patient reported to 
be RM28,070.00 (US$7999.00). In 
Germany, Steinke et al. (2013) revealed 
that yearly costs per patient added 
up to RM38,844.34 (€7,092.00). In 
a systematic review, Obradors et al. 
(2014) discovered that the annual total 
cost of the treatment of psoriasis in 
Europe (from the social perspective) 
was between RM6,349.00 (€1,340.00) 
and RM39,104.00 (€8,253.00). 
Because our health care system is 
heavily subsidised, the estimated costs 
of the treatment of psoriasis are far 
lower than other countries. In addition, 
the use of expensive drugs such as 
biologics is still limited in this country 
which explains the lower cost of the 
treatment to psoriasis in this cohort 
compared to other countries (Tang et 
al. 2013). 
 Our findings showed that medication 
appeared to be most significant aspects 
(90%) and this is in line with previous 
analysis conducted in European 
countries (Beyer & Wolverton 2010; 
Obradors et al. 2014). Productivity 
loss is not uncommon among psoriasis 
patients.  In fact, it surpasses the aspect 
of direct costs among patients with 
psoriasis (Raho et al. 2012; Schmitt 
& Ford 2006), approved the greatest 
cost. Generally, about 15% to 60% of 
workers with psoriasis  are absent from  
work with an average of 26 days/year 
(De Arruda & De Moraes 2001; Mattila 
et al. 2013). In Taiwan, the cost due to 
reduced productivity accounted for 
30-50% of the total expenses (Chen et 
al., 2014). 
 Biologics and systemic treatments 
have higher cost due to medication 
and monitoring costs. This is 
especially relevant as systemic agents 
Recurrent 
and capital 
cost  (RM)
(2015)
Apportion r1 Annual cost of medical r
2
Annual 
cost of 
psoriasis
Patient 
days/
visits
Cost per 
patient 
per day/
visit 
524,498,225. 
41
314,698,935.25 
(a) (60%)
0.18
(b)
56,645,808.34
(c)
0.0017
(d)
98,587.49
(e)
89.2
(f)
1,105.24
(g)
209,799,290.11
(1)(40%)
0.31
(2)
65,419,250.44
(3)
0.0021
(4)
138,698.98
(5)
465.4
(6)
298.02
(7)
*r1= ratio inpatient days/outpatient visit medical to hospital, r2= ratio inpatient day/outpatient visits psoriasis 
to medical
Table 4: Inpatient and outpatient cost  
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such as methotrexate, acitretin and 
cyclosporine have significant side-
effects and cumulative toxicity. 
Therefore, laboratory tests need to 
be conducted to identify those who 
are at risk at developing toxicity 
(Ministry of Health, 2013). The price 
for systemic and biologic drugs are 
more costly compared to traditional 
therapies (Beyer & Wolverton, 2010). 
The estimated annual cost of biologic 
treatment varied from RM160,654.00 
($36,038.00) (adalimumab) to 
RM200,267.00 (US$44,924) 
(ustekinumab) in the year 2013 (Cheng 
& Feldman, 2014). 
 Phototherapy is indicated for 
patients with moderate psoriasis where 
topical treatment has failed (Ministry 
of Health 2013). In this analysis, 
there is a smaller number of patients 
receiving this treatment. The possible 
explanation for this is because patients 
find it challenging to attend the clinic 
for phototherapy sessions for two (2) 
or three (3) days a week as they have 
to miss work which subsequently 
affects their income. It also requires 
many resources from the provider 
(Mustonen et al. 2014). In terms of 
cost, phototherapy has the least cost 
and the possible explanation for this 
is because of the lower number of 
patients receiving this modality in 
our analysis. Phototherapy may result 
in economic burden to patients and 
the provider. In a study conducted 
by Langan et al. (2004), it was found 
Component of cost Modalities P value
Topical 
(n=32)
Topical and 
phototherapy 
(n=9)
Topical and 
systemic 
(n=40)
Topical and 
biologic 
(n=10)
Provider (RM)
P<0.005
Medication 27,920.00 17,608.00 17,191.00 333,295.00
Lab tests 9,810.00 4,116.00 26,565.00 8,838.00
Radiology 550.00 100.00 850.00 244.00
Cost per patient (RM) 1,196.25 2,424.89 2,640.15 34,237.70
Patient (RM)
Out of pocket 
payments
8,430.00 5,650.00 4,250.00 2,280.00
P<0.005
Traveling cost 2,841.00 1,645.00 3,960.00 1,825.00
Loss of productivity 26,778.00 73,170.00 59,412.00 8,088.00
Cost per patient (RM) 1,189.03 8,960.56 1,690.55 1,219.30
Overall cost 76,329.00 102,289.00 173,228.00 354,570.00
*All costs were calculated for six months duration, ANOVA, significant, p<0.005
Table 5: Costs according to modalities 
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that the yearly cost of narrowband 
UVB was RM306,906.00 (€53,555.00) 
in Ireland with a mean cost per 
patient at RM1,862.00 (€325). Staffing 
was the most significant aspect, 
accounting for 70% of the cost. Recent 
evidence suggested that annual cost 
of narrowband UVB phototherapy 
at RM8,218.00 (US$1,734.00) was 
lesser than other treatment modalities: 
RM20,073.00 (US$4,235.00) for 
PUVA, RM36,818.00 (US$7,768.00) 
for cyclosporin, RM43,430.00 
($9,163.00) for acitretin, RM111,565.00 
(US$23,538.00) for adalimumab, 
RM112,043.00 (US$23,639.00) 
for infliximab, RM115,835.00 
(US$24,439.00) for eanercept except 
for methotrexate, at RM5,673.00 
(US$1197.00) (Beyer & Wolverton 
2010). 
 A major strength of our study was 
that this was the first study conducted 
in Malaysia to estimate the cost of 
treatment for psoriasis and hence, it 
was able to provide important input 
to policy makers in the allocation of 
resources. This is a comprehensive 
economic evaluation which includes 
all available treatment modalities and 
costs that were evaluated from both 
perspectives (provider and patient). 
A Clinical Pathway (CP) for moderate 
to severe psoriasis patients was 
specifically developed for the data 
collection in this study. Due to the 
detailed care plan (illustrated in the CP), 
true estimation of cost in each activity 
of treatment (Ismail et al. 2016) was 
provided. The main limitation of this 
study was short time horizon. Psoriasis 
is a long-term disease and its treatment 
lasts for lifetime, therefore, it would 
be ideal for an economic evaluation 
to measure costs associated with the 
changes and interruptions during 
treatment for many years. In addition, 
cost of side effects and comorbidities 
were excluded in the analysis. These 
factors could influence overall cost of 
the treatments.   
CONCLUSION
Our study showed that patients 
receiving the topical along with 
biologic treatment incur an overall 
highest cost compared to other classic 
interventions when prescribed in an 
outpatient setting. Understanding 
the relationship between direct and 
indirect costs from both perspectives 
is necessary to accurately identify 
and evaluate effective treatments for 
psoriasis. 
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